Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andres Jan Schrader

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
Aktuelle Urologie|April 23, 2024
["Pressure kills kidneys": protection of the upper urinary tract through neuro-urological management]Fabian Queißert, Andres Jan Schrader
Anti-Cancer Drugs|May 31, 2008
Metastatic renal cell carcinoma: recent advances and current therapeutic optionsAndres Jan Schrader, Rainer Hofmann
ISRN Urology|July 11, 2012
Renal Cell Carcinoma Update: News from the AUA, EAU, and ASCO Annual Meetings 2011Andres Jan Schrader, Sandra Steffens
European Urology|January 7, 2011
Re: Beat Roth, Frédéric D. Birkhäuser, Pascal Zehnder, et al. Readaptation of the peritoneum following extended pelvic lymphadenectomy and cystectomy has a significant beneficial impact on early postoperative recovery and complications: results of a prospective randomized trial. Eur Urol 2011;59:204-10Florian Jentzmik, Andres Jan Schrader, Mark Schrader
Annals of Translational Medicine|February 5, 2020
Considerations for AR-V7 testing in clinical routine practiceChristof Bernemann, Laura-Maria Krabbe, Andres Jan Schrader
Clinical and Translational Medicine|July 23, 2014
Clinical significance of epithelial-mesenchymal transitionKonrad Steinestel, Stefan Eder, Andres Jan Schrader, et al.
World Journal of Surgical Oncology|August 9, 2014
Positive surgical margins in nephron-sparing surgery: risk factors and therapeutic consequencesJulie Steinestel, Sandra Steffens, Konrad Steinestel, et al.
Aktuelle Urologie|May 30, 2019
[Radical prostatectomy through the years]Andres Jan Schrader, Johannes Müller, Martin Janssen, et al.
Current Cancer Drug Targets|February 6, 2015
Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC)Martin Boegemann, Andres-Jan Schrader, Laura-Maria Krabbe, et al.
Oncology Research and Treatment|May 21, 2020
[mHSPC-Therapie mit Apalutamid/ADT]Ekkehardt Bismarck, Peter Hammerer, Axel S Merseburger, et al.
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Aktuelle Urologie|April 23, 2024
["Pressure kills kidneys": protection of the upper urinary tract through neuro-urological management]Fabian Queißert, Andres Jan Schrader
Anti-Cancer Drugs|May 31, 2008
Metastatic renal cell carcinoma: recent advances and current therapeutic optionsAndres Jan Schrader, Rainer Hofmann
ISRN Urology|July 11, 2012
Renal Cell Carcinoma Update: News from the AUA, EAU, and ASCO Annual Meetings 2011Andres Jan Schrader, Sandra Steffens
European Urology|January 7, 2011
Re: Beat Roth, Frédéric D. Birkhäuser, Pascal Zehnder, et al. Readaptation of the peritoneum following extended pelvic lymphadenectomy and cystectomy has a significant beneficial impact on early postoperative recovery and complications: results of a prospective randomized trial. Eur Urol 2011;59:204-10Florian Jentzmik, Andres Jan Schrader, Mark Schrader
Annals of Translational Medicine|February 5, 2020
Considerations for AR-V7 testing in clinical routine practiceChristof Bernemann, Laura-Maria Krabbe, Andres Jan Schrader
Clinical and Translational Medicine|July 23, 2014
Clinical significance of epithelial-mesenchymal transitionKonrad Steinestel, Stefan Eder, Andres Jan Schrader, et al.
World Journal of Surgical Oncology|August 9, 2014
Positive surgical margins in nephron-sparing surgery: risk factors and therapeutic consequencesJulie Steinestel, Sandra Steffens, Konrad Steinestel, et al.
Aktuelle Urologie|May 30, 2019
[Radical prostatectomy through the years]Andres Jan Schrader, Johannes Müller, Martin Janssen, et al.
Current Cancer Drug Targets|February 6, 2015
Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC)Martin Boegemann, Andres-Jan Schrader, Laura-Maria Krabbe, et al.
Oncology Research and Treatment|May 21, 2020
[mHSPC-Therapie mit Apalutamid/ADT]Ekkehardt Bismarck, Peter Hammerer, Axel S Merseburger, et al.
Pageof 8